BridgeBio Pharma, Inc. Severance Costs
BridgeBio Pharma, Inc. (BBIO) reported Severance Costs of $4.67 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2026-02-24
- BridgeBio Pharma, Inc. severance costs for the quarter ending 2025-12-31 was $1.50M, a 78.10% increase year-over-year.
- BridgeBio Pharma, Inc. severance costs for the quarter ending 2025-09-30 was $2.94M, a 69.47% increase year-over-year.
- BridgeBio Pharma, Inc. severance costs for the quarter ending 2025-06-30 was $93.00K, a 82.71% decline year-over-year.
- BridgeBio Pharma, Inc. severance costs for the quarter ending 2025-03-31 was $136.00K, a 93.08% decline year-over-year.
- BridgeBio Pharma, Inc. severance costs for fiscal 2025 was $4.67M, a 8.11% decline from fiscal 2024.
- BridgeBio Pharma, Inc. severance costs for fiscal 2024 was $5.08M, a 610.35% increase from fiscal 2023.
- BridgeBio Pharma, Inc. severance costs for fiscal 2023 was $715.00K, a 93.06% decline from fiscal 2022.
- BridgeBio Pharma, Inc. severance costs for fiscal 2022 was $10.31M.
| Period end | Severance Costs 3 month | Severance Costs 6 month | Severance Costs 9 month | Severance Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $4.44M derived: sum of 2 quarters · filed 2026-02-24 | $4.53M derived: sum of 3 quarters · filed 2026-02-24 | $4.67M 10-K · filed 2026-02-24 |
| 2025-09-30 | $2.94M 10-Q · filed 2025-10-29 | $3.04M derived: sum of 2 quarters · filed 2025-10-29 | $3.17M 10-Q · filed 2025-10-29 | $4.01M derived: sum of 4 quarters · filed 2026-02-24 |
| 2025-06-30 | $93.00K 10-Q · filed 2025-08-05 | $229.00K 10-Q · filed 2025-08-05 | $1.07M derived: sum of 3 quarters · filed 2026-02-24 | $2.81M derived: sum of 4 quarters · filed 2026-02-24 |
| 2025-03-31 | $136.00K 10-Q · filed 2025-04-29 | $976.00K derived: sum of 2 quarters · filed 2026-02-24 | $2.71M derived: sum of 3 quarters · filed 2026-02-24 | $3.25M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-12-31 | $840.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.58M derived: sum of 2 quarters · filed 2026-02-24 | $3.11M derived: sum of 3 quarters · filed 2026-02-24 | $5.08M 10-K · filed 2026-02-24 |
| 2024-09-30 | $1.74M 10-Q · filed 2025-10-29 | $2.27M derived: sum of 2 quarters · filed 2025-10-29 | $4.24M 10-Q · filed 2025-10-29 | $4.24M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $538.00K 10-Q · filed 2025-08-05 | $2.50M 10-Q · filed 2025-08-05 | $2.50M derived: sum of 3 quarters · filed 2026-02-24 | $2.50M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $1.97M 10-Q · filed 2025-04-29 | $1.97M derived: sum of 2 quarters · filed 2026-02-24 | $1.97M derived: sum of 3 quarters · filed 2026-02-24 | $2.54M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $572.00K derived: sum of 3 quarters · filed 2026-02-24 | $715.00K 10-K · filed 2026-02-24 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $572.00K derived: sum of 2 quarters · filed 2024-11-12 | $715.00K 10-Q · filed 2024-11-12 | $612.00K derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $572.00K 10-Q · filed 2024-08-01 | $715.00K 10-Q · filed 2024-08-01 | $612.00K derived: sum of 3 quarters · filed 2025-02-20 | $1.61M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $143.00K 10-Q · filed 2024-05-02 | $40.00K derived: sum of 2 quarters · filed 2025-02-20 | $1.04M derived: sum of 3 quarters · filed 2025-02-20 | $3.43M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | -$103.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $894.00K derived: sum of 2 quarters · filed 2025-02-20 | $3.29M derived: sum of 3 quarters · filed 2025-02-20 | $10.31M 10-K · filed 2025-02-20 |
| 2022-09-30 | $997.00K 10-Q · filed 2023-11-02 | $3.39M derived: sum of 2 quarters · filed 2023-11-02 | $10.41M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $2.40M 10-Q · filed 2023-08-03 | $9.41M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $7.02M 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |